Study S000072

A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus® (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

ClinicalTrials.gov record

Registration

Registration: NCT05714683
Study type: OBSERVATIONAL
Status: NOT_YET_RECRUITING
Enrollment: 600
Start: 2027-01-31
Primary completion: 2027-08-30
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1243-9500

Registered primary outcomes

Number (Incidence) of adverse events (AEs) [From baseline (week 0) to 26 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.